ISSUE 1
Special Issue: Anti-Tumor CAR-T Cell Therapy
Guest Editor: Geraldo Passos

Preface of the Special Issue “Anti-Tumor CAR-T Cell Therapy”
G. Passos

Current Challenges and Strategies for Chimeric Antigen Receptor–T-Cell Therapy for Solid Tumors
J. Chen & H. Jiang

Implications of TET2 in CAR-T Cell Activity and Target Response to CAR-T Cell Therapy: Lessons Learned from T Cells
S. Pasca, A. Jurj, C. Constantinescu, M. Zdrenghea, & C. Tomuleasa

Current Headway in Cancer Immunotherapy Emphasizing the Practice of Genetically Engineered T Cells to Target Selected Tumor Antigens
S.K. Ray & S. Mukherjee

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

In Search of an Ideal CAR-T Cell Antigen Target
L.R. Carvalho Barros

CAR-T Cell Therapy: Challenges and Optimization
M. Luo, H. Zhang, L. Zhu, Q. Xu, & Q. Gao

Structural Determinants of Chimeric Antigen Receptor Design
L. Abdo, E.A. Aragão, & M.H. Bonamino

ISSUE 2
Special Issue: Use of NK Cells in Cancer Immunotherapy: Successes and Challenges
Guest Editor: Anahid Jewett

Preface: Use of NK Cells in Cancer Immunotherapy: Successes and Challenges
A. Jewett

Probiotics in Health and Disease: Distinct Roles of Different Strains in Natural Killer Cell Activation and Regulation

Role of GATA2 in Human NK Cell Development
D. Wang, B. Uyemura, E. Hashemi, S. Bjorgaard, M. Riese, J. Verbsky, M.S. Thakar, & S. Malarkannan

NK Cell Development and Function in Patients with Fanconi Anemia
E. Hashemi, S. Bjorgaard, D. Wang, B. Uyemura, M. Riese, M.S. Thakar, & S. Malarkannan

Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy
R. Touboul, A. Zaravinos, & B. Bonavida

Myeloid-Derived Suppressor Cells Hamper Natural Killer Cell Activity in Cancer: Role of
Peptidases
T. Jakoš, A. Pišlar, A. Jewett, & J. Kos

Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
J. Wu

Issue 3
Special Issue: Immune Response to Viruses
Guest Editor: Shashank Tripathi

PREFACE: Immune Response to Viral Infections
S. Tripathi

Role of CD8+ T Cells in Immunity against Flaviviruses
V. Satchidanandam

Severe Cases of COVID-19 and High Association with Causes of Immune Dysregulation: A Systematic Review

Innate Immune Subversion Strategies of Human Flaviviruses
S. Kaur & S. Tripathi

Dysregulated Innate Immune and Inflammatory Responses in SARS-CoV-2 Infection and COVID-19 Severity
P. Ghosh, S. Nagaraja, S. Basavaraju, & S. Kesavardhana

Human Innate Lymphoid Cells in Influenza Infection and Vaccination
A. Kumar, R. Kumari, T. Liu, W. Cao, B.A. Davidson, P.R. Knight, & S. Sambhara

Issue 4
Special Issue: Unconventional T Cells in Health and Disease
Guest Editor: Luc Van Kaer

Preface: Unconventional T Cells in Health and Disease
L. Van Kaer

Role of Group 1 CD1–Restricted T Cells in Host Defense and Inflammatory Diseases
E. Morgun, L. Cao, & C.-R. Wang

Unconventional Intestinal Intraepithelial Lymphocytes in Health and Disease
A. Nazmi, K.G. McClanahan, & D. Olivares-Villagómez

Involvement of Qa-1/HLA-E-Restricted CD8+ T Cells in Anti-Microbe and Anti-Cancer Immunity as Well as in Immune Regulation
H. Sheng, S. Dasgupta, & V. Kumar

Natural Killer T Lymphocytes Integrate Innate Sensory Information and Relay Context to Effector Immune Responses
S. Joyce, G.D. Okoye, & L. Van Kaer

Issue 5
Special Issue: MAIT Cells in Viral Diseases
Guest Editor: S.M. Mansour Haeryfar

Preface: MAIT Cells in Viral Diseases
S.M. Mansour Haeryfar

Mucosal-Associated Invariant T Cells: Diplomatic Front-Runners in the Fight against Hepatitis B Virus Infection
H.-Y. Tan, Y.-K. Yong, C.S. Ng, J. Vimali, R. Mohamed, A. Murugesan, V. Velu, M. Larsson, & E.M. Shankar

MAIT Cells in Respiratory Viral Infections in Mouse and Human
Y. Long & T.S.C. Hinks
MAIT Cells in Viral Hepatitis and Liver Diseases  
B. Binder, R. Thimme, & M. Hofmann

Viral Impacts on MR1 Antigen Presentation to MAIT Cells  
C. Samer, R. Traves, S.K. Purohit, A. Abendroth, H.E.G. McWilliam, & B. Slobedman

MAIT Cell Loss and Reconstitution in HIV-1 Disease  
F. Han, Y. Zheng, A. Ho, S. Ma, J.K. Sandberg, & E. Leeansyah

ISSUE 6
Special Issue: Microbiome-Immune System Interactions
Guest Editors: Geraldo Passos and Vipin Kumar Chaturvedi

Preface Special Issue: Microbiome–Immune System Interactions  
G.A. Passos & V.K. Chaturvedi

Selective Immunoglobulin A Deficiency and the Microbiome  
J. Galant-Swafford

The Role of the Microbiome in Sjögren’s Syndrome  
M. Maślińska, K. Kostyra-Grabczak, L. Królicki, & B. Kwiatkowska

Potential Immune-Microbiome Interactions in Breast Cancer May Advance Treatment:  
What’s Holding Us Back?  
A.D. Swafford, S. Khandelwal, & S. Bhute

Index, Volume 41, 2021
Abdo, L., 89
Abendroth, A., 49
Aragão, E.A., 89
Basavaraju, S., 43
Beutinger Marchioro, S., 15
Bhute, S., 27
Binder, B., 37
Bjorgaard, S., 21, 35
Bonamino, M.H., 89
Bonavida, B., 45
Borges Ribeiro, M., 15
Brand, H., 41
Breznik, B., 1
Brito de Morais, I.R., 15
Cao, L., 1
Cao, W., 57
Carvalho Barros, L.R., 41
Carvalho Fantacini, D.M., 41
Chaturvedi, V.P., v
Chen, J., 1
Chen, P.-C., 1
Chovatiya, N., 1
Constantinescu, C., 13
Dasgupta, S., 39
Davidson, B.A., 57
de Castro Batista, L., 41
de Lima, S.C.G., 41
de Souza, L.E.B., 41
Furtado, I.P., 41
Galant-Swafford, J., 1
Gao, Q., 77
Ghosh, P., 43
Han, F., 69
Hashemi, E., 21, 35
Hinks, T.S.C., 19
Ho, A., 69
Hofmann, M., 37
Jakoš, T., 77
Jewett, A., v, 1, 77
Jiang, H., 1
Joyce, S., 55
Jurj, A., 13
Kaur, K., 1
Kaur, S., 27
Kesavardhana, S., 43
Khandelwal, S., 27
Knight, P.R., 57
Ko, M.-W., 1
Kos, J., 77
Kostyra-Grabczak, K., 13
Królicki, L., 13
Kumar, A., 57
Kumar, V., 39
Kumari, R., 57
Kwiatkowska, B., 13
Larsson, M., 1
Leeansyah, E., 69
Liu, T., 57
Long, Y., 19
Luo, M., 77
Ma, S., 69
Malarkannan, S., 21, 35
Mansour Haerifar, S.M., v
Maraninchi Silveira, R., 41
Mašlińska, M., 13
McClanahan, K.G., 23
McWilliam, H.E.G., 49
Menezes Freire, S., 15
Meyer Nascimento, R.J., 15
Mohamed, R., 1
Morgun, E., 1
Mukherjee, S., 23
Murugesan, A., 1
Nagaraja, S., 43
Nazmi, A., 23
Ng, C.S., 1
Okoye, G.D., 55
Olivas-Ruíz-Villagómez, D., 23
Pasca, S., 13
Passos, G.A., v
Pišlar, A., 77
Purohit, S.K., 49
Ray, S.K., 23
Riese, M., 21, 35
Rossetti, R., 41
Sambhara, S., 57
Samer, C., 49
Sandberg, J.K., 69
Satchidanandam, V., 1
Senjor, E., 1
Shankar, E.M., 1
Sheng, H., 39
Slobedman, B., 49
Swafford, A.D., 27
Tadeu Covas, D., 41
Tan, H.-Y., 1
Thakar, M.S., 21, 35
Thimme, R., 37
Tomuleasa, C., 13
Torres, A.J.L., 15
Touboul, R., 45
Traves, R., 49
Tripathi, S., v, 27
Uyemura, B., 21
Uyemura, B., 35
Van Kaer, L., v, 55
Velu, V., 1
Verbsky, J., 21
Vimali, J., 1
Wang, C.-R., 1
Wang, D., 21, 35
Wang, Y., 1
Wong, P., 1
Wu, J., 101
Xu, Q., 77
Yong, Y.-K., 1
Zaravinos, A., 45
Zdrenghea, M., 13
Zhang, H., 77
Zheng, Y., 69
Zhu, L., 77
| animal models | 1 | genetically engineered T-cell therapy | 23 |
| anagonism | 27 | gut microbiome | 1 |
| antigen presentation | 1 | HBV | 1 |
| antigen | 69 | hepatocellular carcinoma | 1 |
| autoimmune | 1, 13 | HIV-1 | 69 |
| breast cancer | 27 | human tumor antigens | 23 |
| cancer immunotherapy | 1, 23 | human | 19 |
| cancer stem cells (CSCs) | 1 | humanized-BLT mice | 1 |
| cancer | 41, 77 | IFN-γ | 1 |
| CAR design | 89 | immune dysregulation | 1, 15 |
| CAR structure | 89 | immune regulatory | 39 |
| CAR-T cell | 69 | immunology | 27 |
| CAR-T cells | 13 | immunopathogenesis | 69 |
| CAR-T | 23, 41 | immunopathology | 1 |
| CD1 | 1 | immunosuppression | 77 |
| CD8 T | 39 | immunotherapy | 1, 45, 101 |
| CD8+ T cells | 1 | improvement | 77 |
| cell therapy | 41 | infection | 1, 19 |
| chimeric antigen receptor | 8 | inflammation | 1 |
| chimeric antigen receptor–T cell | 1 | inflammatory cell death | 43 |
| clinical applications | 77 | influenza vaccine | 57 |
| common variable | immunity | innate immunity | 27, 43, 57 |
| immunodeficiency | 1 | innate lymphoid cells | 57 |
| COVID-19 | 15, 19, 43 | innate | 19 |
| cytotoxicity | 1 | interferon | 27 |
| defect in signaling | 45 | MAIT cell | 1 |
| development | 55, 77 | MAIT cells | 69 |
| differentiation | 1 | melanoma | 45 |
| DNA damage | 35 | microbiome | 13, 27 |
| dysbiosis | 13 | microbiota | 1 |
| evasion | 27 | molecular mimicry | 13 |
| evolution | 55 | mouse | 19 |
| Fanconi anemia | 35 | mucosal immunity | 69 |
| flavivirus | 1 | mucosal-associated invariant T cell | 19 |
| flaviviruses | 27 | myeloid-derived suppressor cells | 77 |
| function | 55 | NAFLD | 1 |
| GATA2 | 21 | natural killer cells | 77 |
| gene editing | 41 | NK cell development | 21 |
| | | NK cell | 21, 101 |
| | | NK cells | 1, 35 |
| | | NK | 45 |
| | | NKG2D | 45 |
| | | NKT cells | 55 |
| | | nonclassical MHC | 39 |
| | | organoids | 69 |
| | | osteoclasts | 1 |
| | | peptidases | 77 |
| | | primary immunodeficiency | 1 |
| | | probiotics | 1 |
| | | pro-inflammatory cytokines | 43 |
| | | prostate cancer | 101 |
| | | protection | 1 |
| | | resistance | 45 |
| | | respiratory infection | 43 |
| | | review | 19 |
| | | SARS-CoV-2 | 15, 43 |
| | | severe COVID-19 | 15 |
| | | signaling domains | 89 |
| | | Sjögren’s syndrome | 13 |
| | | solid tumor | 1 |
| | | super-charged NK cells | 1 |
| | | T cells | 1, 13, 19 |
| | | TCR T-cell therapy | 23 |
| | | TCR | 41 |
| | | TCRβ+CD4+CD8αα+, 23 |
| | | TCRβ+CD8αα+, 23 |
| | | TCRγδ | 23 |
| | | TET2 | 13 |
| | | toxicity | 77 |
| | | transcriptional factor | 39 |
| | | tumor immunity | 1 |
| | | tumor microenvironment | 1, 27 |
| | | vaccine design | 1 |
| | | virus clearance | 1 |
| | | virus | 19 |